Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis.


Journal

Oncogenesis
ISSN: 2157-9024
Titre abrégé: Oncogenesis
Pays: United States
ID NLM: 101580004

Informations de publication

Date de publication:
19 Nov 2020
Historique:
received: 03 02 2020
accepted: 30 10 2020
revised: 22 10 2020
entrez: 20 11 2020
pubmed: 21 11 2020
medline: 21 11 2020
Statut: epublish

Résumé

Lung cancer mortality largely results from metastasis. Despite curative surgery many patients with early-stage non-small cell lung cancer ultimately succumb to metastatic relapse. Current risk reduction strategies based on cytotoxic chemotherapy and radiation have only modest activity. Against this background, we functionally screened for novel metastasis modulators using a barcoded shRNA library and an orthotopic lung cancer model. We identified aryl hydrocarbon receptor (AHR), a sensor of xenobiotic chemicals and transcription factor, as suppressor of lung cancer metastasis. Knockdown of endogenous AHR induces epithelial-mesenchymal transition signatures, increases invasiveness of lung cancer cells in vitro and metastasis formation in vivo. Low intratumoral AHR expression associates with inferior outcome of patients with resected lung adenocarcinomas. Mechanistically, AHR triggers ATF4 signaling and represses matrix metalloproteinase activity, both counteracting metastatic programs. These findings link the xenobiotic defense system with control of lung cancer progression. AHR-regulated pathways are promising targets for innovative anti-metastatic strategies.

Identifiants

pubmed: 33214553
doi: 10.1038/s41389-020-00286-8
pii: 10.1038/s41389-020-00286-8
pmc: PMC7677369
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102

Références

Cell. 2017 Feb 9;168(4):670-691
pubmed: 28187288
Nature. 2011 Oct 05;478(7368):197-203
pubmed: 21976023
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
Genes Dev. 2000 Jan 15;14(2):163-76
pubmed: 10652271
Genome Biol. 2010;11(3):R25
pubmed: 20196867
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Mol Nutr Food Res. 2006 Oct;50(10):897-907
pubmed: 16977593
Nat Cell Biol. 2018 Jul;20(7):782-788
pubmed: 29941931
N Engl J Med. 2004 Jan 22;350(4):351-60
pubmed: 14736927
Cell Metab. 2018 Feb 6;27(2):428-438.e5
pubmed: 29337136
N Engl J Med. 2005 Jun 23;352(25):2589-97
pubmed: 15972865
N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
Sci Rep. 2016 May 17;6:26091
pubmed: 27184933
EMBO J. 2010 Jun 16;29(12):2082-96
pubmed: 20473272
Br J Cancer. 2010 Feb 2;102(3):561-9
pubmed: 20051957
J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):201-12
pubmed: 20440544
Int J Mol Sci. 2014 May 06;15(5):7939-57
pubmed: 24806346
Int J Mol Sci. 2018 Nov 15;19(11):
pubmed: 30445691
Oncoimmunology. 2017 Apr 28;6(6):e1320626
pubmed: 28680756
Cancer Res. 2015 Nov 1;75(21):4651-64
pubmed: 26363006
J Clin Oncol. 2015 Dec 10;33(35):4194-201
pubmed: 26527789
BMC Cancer. 2014 Jul 09;14:498
pubmed: 25011475
Cancer Cell. 2018 Jan 8;33(1):91-107.e6
pubmed: 29316436
Nat Genet. 2017 Jan;49(1):87-96
pubmed: 27869830
Clin Cancer Res. 2007 Jan 1;13(1):38-45
pubmed: 17200336
PLoS One. 2013 Dec 18;8(12):e82241
pubmed: 24367507
Sci Rep. 2017 Feb 14;7:41927
pubmed: 28195146
Nat Cell Biol. 2018 Jul;20(7):775-781
pubmed: 29941933
J Biol Chem. 2004 Dec 3;279(49):50829-39
pubmed: 15385533
Anal Biochem. 1994 May 1;218(2):325-9
pubmed: 8074288
Cancer Lett. 2016 Jul 1;376(2):211-7
pubmed: 27060206
Cell Res. 2009 Jan;19(1):89-102
pubmed: 19050696
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Arch Toxicol. 2017 May;91(5):2165-2178
pubmed: 27752740
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cancer Res. 2019 Nov 1;79(21):5550-5562
pubmed: 31431462
Anticancer Res. 2013 Apr;33(4):1247-56
pubmed: 23564762
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
Lancet Oncol. 2018 Jan;19(1):139-148
pubmed: 29174310
Surg Oncol. 2012 Mar;21(1):23-9
pubmed: 20801643
FEBS Lett. 2016 Jul;590(14):2063-75
pubmed: 27282934
Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):695-701
pubmed: 18439766
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Lancet Oncol. 2006 Sep;7(9):719-27
pubmed: 16945766

Auteurs

Silke Nothdurft (S)

Laboratory of Molecular Oncology, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Clotilde Thumser-Henner (C)

Laboratory of Molecular Oncology, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Frank Breitenbücher (F)

Laboratory of Molecular Oncology, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Ross A Okimoto (RA)

Department of Medicine, University of California, San Francisco, CA, USA.
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.

Madeleine Dorsch (M)

Laboratory of Molecular Tumor Pathology, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.

Christiane A Opitz (CA)

DKTK Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Neurology Clinic and National Center for Tumor Diseases, University Hospital of Heidelberg, Heidelberg, Germany.

Ahmed Sadik (A)

DKTK Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Faculty of Bioscience, Heidelberg University, Heidelberg, Germany.

Charlotte Esser (C)

IUF-Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany.

Michael Hölzel (M)

Institute of Experimental Oncology, University Hospital Bonn, University of Bonn, Bonn, Germany.

Saurabh Asthana (S)

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.

Jan Forster (J)

German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.

Daniela Beisser (D)

Department of Biodiversity, University Duisburg-Essen, Essen, Germany.

Sophie Kalmbach (S)

Laboratory of Molecular Oncology, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Barbara M Grüner (BM)

Laboratory of Molecular Tumor Pathology, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Trever G Bivona (TG)

Department of Medicine, University of California, San Francisco, CA, USA.
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.

Alexander Schramm (A)

Laboratory of Molecular Oncology, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany. Alexander.Schramm@uk-essen.de.

Martin Schuler (M)

Laboratory of Molecular Oncology, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany.

Classifications MeSH